[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pre-gestational-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pre-gestational-diabetes":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,81,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053652","automated-insulin-for-management-of-intrapartum-glycemia-100053652",false,"NCT06883344","Automated Insulin for Management of Intrapartum Glycemia","Automated Insulin for Management of Intrapartum Glycemia (AIMING): a Multicenter Randomized Controlled Trial","AIMING","Inclusion Criteria:\n\n* Currently pregnant at ≥ 34 weeks\n* Known diagnosis of type 1 diabetes ≥ 1 year\n* Use of commercially available AID system since at least 28 weeks gestation\n* Singleton pregnancy\n* English- or Spanish-speaking\n\nExclusion Criteria:\n\n* Multifetal gestation\n* Planned cesarean delivery\n* Use of medications known to interfere with glucose metabolism\n* Intrauterine fetal demise\n* Physical or psychological disease likely to interfere with the conduct of the study and\u002For the ability to participate in own healthcare","FEMALE","18 Years","55 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor\u002Fdelivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are\n\n* What are the neonatal glycemic outcomes with use of AID systems during labor\u002Fdelivery?\n* Do patients report higher birth satisfaction with use of AID systems during labor\u002Fdelivery?\n* Are glycemic parameters like time-in-range (TIR) better with use of AID systems during labor\u002Fdelivery?\n\nResearchers will compare AID systems to intravenous (IV) insulin (the current standard of care for glucose management during labor\u002Fdelivery) by randomly assigning participants to one or the other.",[28,29,30],"Type 1 Diabetes (T1D)","Pregnancy","Pre-Gestational Diabetes",[29,32,33,34,35],"Intrapartum glycemic management","Neonatal hypoglycemia","Perinatal care","Diabetes in pregnancy","RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2025-12-05",{"date":44,"type":22},"2028-12-31",{"name":46,"class":47},"University of California, San Francisco","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100490156","successfully-achieving-and-maintaining-euglycemia-during-pregnancy-for-type-2-diabetes-through-technology-and-coaching-100490156","NCT05662462","Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching","ACHIEVE: Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching","Inclusion Criteria:\n\n1. pregnant individuals age ≥18 years;\n2. ≤20 weeks of gestation (specifically, \\\u003C20+6 weeks);\n3. diagnosis of pregestational T2D and A1c ≥6.5% at the time of study enrollment;\n4. Medicaid insurance;\n5. English or Spanish speaking;\n6. cognitively able to complete the study requirements;\n7. consent to all study activities;\n8. accessible for participation in study activities;\n9. use a smartphone with internet access;\n\nParticipants must also consent to the study team abstracting information from their electronic health records (EHRs), using CGM for glucose monitoring if randomized to the intervention group, tracking the participants' clinic, hospital, and emergency room visits during the study period, as well as tracking the number of times the participants use the ACHIEVE mobile health (mHealth) application (app), including what activities are used in the mobile application (e.g., recording blood glucose, scheduling appointments, messaging their healthcare providers, accessing educational resources).",{"count":57,"type":22},124,[25],"The ACHIEVE RCT will measure the effect of the intervention (mHealth app with CGM, provider dashboard, and care team coaching) compared to current standard care (prenatal visits, self-monitored blood glucose, and certified diabetes care and education specialist) on achieving glycemic control (hemoglobin A1c \\\u003C6.5% in the third trimester). We hypothesize a 25% absolute increase in the proportion of participants in the intervention group who will meet the target hemoglobin A1c \\\u003C6.5% in the third trimester compared to the standard care group",[30,61,62,63],"Type2diabetes","Pregnancy in Diabetic","Pregnancy, High Risk",[65,29,66,67,68,69,70],"mHealth","Type 2 diabetes","Continuous glucose monitoring","Mobile application","Medicaid","Glycemic control","2026-06-24",{"date":73,"type":40},"2026-06-29",{"date":75,"type":40},"2024-07-11",{"date":77,"type":22},"2029-03",{"name":79,"class":47},"Ohio State University",1,{"id":82,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":26,"conditions":85,"keywords":86,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":92,"locationsCount":93},"100583977",{"count":21,"type":22},[25],[28,29,30],[29,32,33,34,35],"2026-05-13",{"date":89,"type":40},"2026-05-18",{"date":42,"type":40},{"date":44,"type":22},{"name":46,"class":47},2,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":80},"100509101","a-randomized-controlled-trial-of-diabetes-screening-immediately-postpartum-dip-and-follow-up-pp-care-100509101","NCT05909046","A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE","A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) - Follow up Study: Patient Perspectives on Postpartum Interventions to Improve Future Maternal CARdiovascular hEalth After Gestational Diabetes (PP CARE)","DIP - Inclusion Criteria:\n\n* Immediately postpartum individuals during their delivery hospital admission\n* ≥ 18 years old with the ability to give informed consent.\n* Diagnosed with GDM during pregnancy by:\n\n  * Elevated one-hour 50-gram glucose challenge test any time during pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis OR\n  * Two elevated values on a 3-hour 100-gram glucose tolerance test any time in pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis\n* English or Spanish speaking\n* Receiving prenatal and postpartum care at OSU\n\nDIP- Exclusion Criteria:\n\n* Individuals who cannot tolerate a 2-hour oral glucose tolerance test (OGTT) (i.e. history of gastric bypass)\n* Not English or Spanish speaking\n\nPP CARE Inclusion criteria: Enrolled DIP participants who are English speaking will be eligible for PP CARE follow up if they are between 12 and 24 months postpartum.\n\nPP CARE Exclusion criteria: Spanish speaking DIP participants will be excluded because the study team does not include anyone who is Spanish speaking.",{"count":102,"type":22},104,[25],"DIP : To conduct a pragmatic, non-blinded randomized controlled trial (pRCT) of immediate in-patient postpartum OGTT prior to delivery discharge (intervention) versus 4-12 week outpatient postpartum OGTT (current standard care) to improve the frequency of post-partum diabetes screening among individuals with a pregnancy complicated by GDM.\n\nFollow up PP CARE: To engage with individuals with a history of GDM through a patient-centered mixed-methods survey and qualitative assessment to evaluate the barriers to and facilitators of Cardiovascular health (CVH) counseling and risk-reduction postpartum at the patient and healthcare system levels inclusive of Social determinants of health (SDOH) and structural factors, as well as patient preferences and perspectives on CVH and wellness interventions",[30,61,62,63,106,107],"Gestational Diabetes","Gestational Diabetes Mellitus in the Puerperium",[109,29,110,111,112,113,114,115],"2-hour oral glucose tolerance test (OGTT)","diabetes mellitus screening","postpartum","cardiometabolic health","cardiovascular health","type 2 diabetes","prediabetes","2025-11-19",{"date":118,"type":40},"2025-11-24",{"date":120,"type":40},"2023-07-24",{"date":122,"type":22},"2026-06-30",{"name":79,"class":47}]